Nxera Pharma Co. Ltd. (TSE: 4565)

https://www.nxera.life

Nxera Pharma (formerly Sosei Heptares) is a technology powered biopharma company, in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally. In addition to several products being commercialized in Japan, we are advancing an extensive pipeline of over 30 active programs from discovery through to late clinical stage internally and in partnership with leading pharma and biotech companies. This pipeline is focused on addressing major unmet needs in some of the fastest-growing areas of medicine across neurology, GI and immunology, metabolic disorders and rare diseases, and leverages the power of our unique and industry leading GPCR-targeted structure-based drug discovery “NxWaveTM” platform to provide a sustainable source of best- or first-in-class candidates. Nxera employs over 350 talented people at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565). *

	Start	2024-04-01 renamed
	Group	Nxera Pharma (Group)
	Predecessor	Sosei Group Corporation (TSE Mothers Index: 4565) (dba Sosei Heptares)
	Industry	pharmaceutical
	Person	Cargill, Chris (Sosei 202307 CEO of Sosei Heptares)

	Region	Tokyo
	Country	Japan
	City	n. a. Tokyo
		Address record changed: 2024-09-06

Basic data	Employees	n. a.

		* Document for »About Section«: Nxera Pharma Co., Ltd.. (9/2/24). "Press Release: Nxera Pharma to Receive US$35 Million from Neurocrine Biosciences upon Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568". Tokyo & Cambridge.

		Record changed: 2025-03-16